[Mofebutazone--evaluation of possible interaction with glibenclamide].
METHODS
In an open clinical trial involving 20 patients, the question was investigated as to whether the administration of 3 x 300 mg mofebutazone daily resulted in any clinically relevant changes in blood sugar levels in diabetics treated with glibenclamide.


RESULTS
Fluctuations observed, both in mean and individual values, were within the range of those regularly seen in diabetics. This was shown by both weekly measurements and a comparison of daily profiles. A comparison of the daily blood sugar profile prior to and after three weeks of mofebutazone, revealed the following mean figures (+/- STD): prior to mofebutazone 12.30 hours 155.5 (+/- 23.2) mg/dl, 16.30 hours 147.2 (+/- 22.0) mg/dl; after 3 weeks of mofebutazone: 12.30 hours 162.7 (+/- 20.0) mg/dl, and 16.30 hours 151.7 (+/- 17.7) mg/dl. No side effects occurred, and no patient left the study prematurely. The laboratory parameters also studied showed no remarkable changes, either in mean values or in individual figures.
Speders
S
S
D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy*; D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D005905:Glyburide / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000097:blood / Q000188:drug therapy*; D010653:Phenylbutazone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001786:Blood Glucose; D010653:Phenylbutazone; C002374:mofebutazone; D005905:Glyburide